Medtronic plc: Financial Report for July 31, 2025

Live Analysis

Medtronic plc (MDT) is currently priced at $91.64, showing a decrease of 80 cents (-0.865%) from the previous close of$ 92.44. The trading volume is $5.32 million, which is 68.32% of the average volume. The asset is experiencing a slight decline in price today.

Earnings Overview

In the latest earnings report for the fourth quarter of 2025, Medtronic plc reported earnings per share of $1.62, surpassing the consensus estimate of$ 1.58. The total revenue for the quarter was $8.93 billion, reflecting a year-over-year increase of 3.94%. The earnings call summary was not provided.

Dividends

Medtronic plc offers a forward dividend yield of 3.1%, with a dividend per share of 71 cents MRQ and $2.81 TTM. The company's consistent dividend payments indicate a stable financial position.

Income Statement

The company's gross profit stands at $5.80 billion, with a gross profit ratio of 65%. Operating income is$ 1.44 billion, resulting in an operating income ratio of 16.09%. Net income for the period is $1 billion, translating to a net income ratio of 11.84%.

Ratios

Key ratios for Medtronic plc include a quick ratio of 1.42, debt ratio of 31.1%, and price-to-earnings ratio of 25.52. These metrics provide insights into the company's financial performance and valuation.

Balance Sheet

Medtronic plc's total assets amount to $91.68 billion, with total liabilities of$ 43.42 billion. The company maintains a strong financial position with significant cash and short-term investments.

Overall, Medtronic plc demonstrates stability in its financial performance and remains an attractive asset for investors.

Key stats

Day's Range

$91.22 - $92.38

Previous Close

$92.44

52-Week Range

$79.29 - $96.25

Market Cap

$117.41B

Volume

Basic EPS (TTM)

3.61

Beta

0.82

About Medtronic

Sector

Healthcare

Industry

Medical Devices

Country

Website

http://www.medtronic.com

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; electrosurgical hardware and instruments, and mesh fixation devices; and gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; colorectal surgeons; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Group segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.